Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of GLM101

Next Previous
X
Search
Trial Profile

Phase 1 study of GLM101

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GLM 101 (Primary)
  • Indications Congenital disorder of glycosylation type 1A
  • Focus Adverse reactions

    • Most Recent Events

    • 17 Dec 2021 According to a Glycomine media release, With successful completion, the company look forward opening enrollment for patients, which is planned for the second half of 2022.
    • 17 Dec 2021 Status changed from planning to recruiting, according to a Glycomine media release.
    • 17 Dec 2021 According to a Glycomine media release, the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for GLM101 for the treatment of PMM2-CDG and has initiated dosing healthy volunteers.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top